2021
Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer
Connolly RM, Leal JP, Solnes L, Huang CY, Carpenter A, Gaffney K, Abramson V, Carey LA, Liu MC, Rimawi M, Specht J, Storniolo AM, Valero V, Vaklavas C, Krop IE, Winer EP, Camp M, Miller RS, Wolff AC, Cimino-Mathews A, Park BH, Wahl RL, Stearns V. Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. Journal Of Clinical Oncology 2021, 39: 2247-2256. PMID: 33999652, PMCID: PMC8260904, DOI: 10.1200/jco.21.00280.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsChemotherapy, AdjuvantFemaleFluorodeoxyglucose F18HumansMiddle AgedNeoadjuvant TherapyPositron Emission Tomography Computed TomographyPredictive Value of TestsRadiopharmaceuticalsReceptor, ErbB-2Time FactorsTrastuzumabTreatment OutcomeUnited StatesConceptsPositron emission tomography-computed tomographyFluorodeoxyglucose positron emission tomography-computed tomographyHER2-positive breast cancerEmission tomography-computed tomographyPathologic complete responseTomography-computed tomographyStandardized uptake valueBreast cancerComplete responseUptake valuePercent changeOne-sided type ITumor maximum standardized uptake valueHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Maximum standardized uptake valuePathological complete responseGrowth factor receptor 2Median percent reductionPositive breast cancerTailoring of therapyLean body massReceiver operator characteristic analysisFactor receptor 2Operator characteristic analysis
2019
Distribution of Mediastinal Lesions Across Multi-Institutional, International, Radiology Databases
Roden AC, Fang W, Shen Y, Carter BW, White DB, Jenkins SM, Spears GM, Molina JR, Klang E, Segni M, Ackman JB, Sanchez EZ, Girard N, Shumeri E, Revel MP, Chassagnon G, Rubinowitz A, Dicks D, Detterbeck F, Ko JP, Falkson C, Sigurdson S, Segreto S, Del Vecchio S, Palmieri G, Ottaviano M, Marino M, Korst R, Marom EM. Distribution of Mediastinal Lesions Across Multi-Institutional, International, Radiology Databases. Journal Of Thoracic Oncology 2019, 15: 568-579. PMID: 31870881, DOI: 10.1016/j.jtho.2019.12.108.Peer-Reviewed Original ResearchConceptsMediastinal lesionsDistribution of lesionsBenign cystsMediastinal compartmentPositron emission tomography-computed tomographyEmission tomography-computed tomographyCommon mediastinal lesionsMulti-institutional cohortTomography-computed tomographyBenign mediastinal cystsParavertebral lesionsThymic carcinomaThymic hyperplasiaMediastinal massNeurogenic tumorsSurgical databaseMediastinal cystsRadiology databaseSingle institutionCommon lesionsMediastinal abnormalitiesDifferential diagnosisMediastinal noduleComputed tomographyDemographic dataAnti-edema and antioxidant combination therapy for ischemic stroke via glyburide-loaded betulinic acid nanoparticles
Deng G, Ma C, Zhao H, Zhang S, Liu J, Liu F, Chen Z, Chen AT, Yang X, Avery J, Zou P, Du F, Lim KP, Holden D, Li S, Carson RE, Huang Y, Chen Q, Kimberly WT, Simard JM, Sheth KN, Zhou J. Anti-edema and antioxidant combination therapy for ischemic stroke via glyburide-loaded betulinic acid nanoparticles. Theranostics 2019, 9: 6991-7002. PMID: 31660082, PMCID: PMC6815966, DOI: 10.7150/thno.35791.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntioxidantsBetulinic AcidBrain EdemaDrug Delivery SystemsDrug Therapy, CombinationDrugs, Chinese HerbalEucommiaceaeGlyburideHumansMaleMiceMice, Inbred C57BLNanoparticlesPentacyclic TriterpenesPositron Emission Tomography Computed TomographyRatsRats, Sprague-DawleyStrokeTriterpenesConceptsBA nanoparticlesFunctional nanomaterialsMultifunctional nanoparticlesAcid nanoparticlesNanoparticlesSingle-agent pharmacotherapyNanomaterialsDrug deliveryCombination therapyComplementary targetTherapeutic benefitPositron emission tomography-computed tomographyEmission tomography-computed tomographyTomography-computed tomographyIschemia-induced infarctionIschemic brainIschemic strokeStroke treatmentBrain penetrabilityBetulinic acidClinical managementEffective pharmacotherapyIntravenous administrationEffective treatmentMost therapeuticsLung Injury on Antiretroviral Therapy in Adults With Human Immunodeficiency Virus/Tuberculosis
Ravimohan S, Auld SC, Maenetje P, Ratsela N, Mlotshwa M, Ncube I, Smith JP, Vangu MD, Sebe M, Kossenkov A, Weissman D, Wallis RS, Churchyard G, Kornfeld H, Bisson GP. Lung Injury on Antiretroviral Therapy in Adults With Human Immunodeficiency Virus/Tuberculosis. Clinical Infectious Diseases 2019, 70: 1845-1854. PMID: 31242296, PMCID: PMC7156779, DOI: 10.1093/cid/ciz560.Peer-Reviewed Original ResearchConceptsPositron emission tomography-computed tomographyHuman immunodeficiency virusTotal glycolytic activityAntiretroviral therapyART initiationLung functionPulmonary tuberculosisLung inflammationLung injuryPulmonary inflammationMycobacteria-specific CD4 T cellsFluorodeoxyglucose positron emission tomography-computed tomographyCD4 T-cell restorationCD4 T cell functionCD4 T cell responsesEmission tomography-computed tomographyHuman immunodeficiency virus/tuberculosisT-cell restorationTB treatment completionWorse lung functionProspective cohort studyHIV/tuberculosisCD4 T cellsFDG PET-CTT cell responses
2016
Simultaneous whole body 18F-fluorodeoxyglucose positron emission tomography magnetic resonance imaging for evaluation of pediatric cancer: Preliminary experience and comparison with 18F-fluorodeoxyglucose positron emission tomography computed tomography
Pugmire B, Guimaraes A, Lim R, Friedmann A, Huang M, Ebb D, Weinstein H, Catalano O, Mahmood U, Catana C, Gee M. Simultaneous whole body 18F-fluorodeoxyglucose positron emission tomography magnetic resonance imaging for evaluation of pediatric cancer: Preliminary experience and comparison with 18F-fluorodeoxyglucose positron emission tomography computed tomography. World Journal Of Radiology 2016, 8: 322-330. PMID: 27028112, PMCID: PMC4807342, DOI: 10.4329/wjr.v8.i3.322.Peer-Reviewed Original ResearchPositron emission tomography-computed tomographyDiffusion-weighted imagingMalignant lesionsPediatric oncology patientsPET-MRIMagnetic resonance imagingPositron emission tomographyBenign lesionsPositron emission tomography-computed tomography examinationFDG maximum standardized uptake valueMinimum apparent diffusion coefficientMaximum standardized uptake valueEmission tomography-computed tomographyOncology patientsWhole-body diffusion-weighted imagingHealth Insurance Portability and Accountability Act-compliantStandard department protocolDetection of malignant lesionsEmission tomographyResonance imagingStandardized uptake valuePositron emission tomography magnetic resonance imagingSingle-center studySuspected cancer diagnosisEPI diffusion-weighted imaging
2015
Cost-Effectiveness Analysis of Routine Surveillance Imaging of Patients With Diffuse Large B-Cell Lymphoma in First Remission
Huntington SF, Svoboda J, Doshi JA. Cost-Effectiveness Analysis of Routine Surveillance Imaging of Patients With Diffuse Large B-Cell Lymphoma in First Remission. Journal Of Clinical Oncology 2015, 33: 1467-1474. PMID: 25823735, DOI: 10.1200/jco.2014.58.5729.Peer-Reviewed Original ResearchMeSH KeywordsCost-Benefit AnalysisDecision Support TechniquesFluorodeoxyglucose F18Health Care CostsHumansImmunotherapyLymphoma, Large B-Cell, DiffuseMarkov ChainsMiddle AgedModels, EconomicMultimodal ImagingPositron-Emission TomographyPredictive Value of TestsQuality-Adjusted Life YearsRadiopharmaceuticalsRemission InductionTime FactorsTomography, X-Ray ComputedTreatment OutcomeConceptsDiffuse large B-cell lymphomaQuality-adjusted life yearsIncremental cost-effectiveness ratioLarge B-cell lymphomaB-cell lymphomaComputed tomographySurveillance imagingCost-effectiveness analysisSurveillance strategiesFirst remissionFluorodeoxyglucose positron emission tomography-computed tomographyPositron emission tomography-computed tomographyEmission tomography-computed tomographyPET/CT scansPET/Computed TomographyFirst-line immunochemotherapyRoutine surveillance imagingMinimal survival benefitDecision-analytic Markov modelLittle clinical benefitRoutine computed tomographyImproved clinical outcomesTomography-computed tomographyCost-effectiveness ratioProbabilistic sensitivity analysesUtility of interim and end-of-treatment [18F]-fluorodeoxyglucose positron emission tomography–computed tomography in frontline therapy of patients with diffuse large B-cell lymphoma
Huntington SF, Nasta SD, Schuster SJ, Doshi JA, Svoboda J. Utility of interim and end-of-treatment [18F]-fluorodeoxyglucose positron emission tomography–computed tomography in frontline therapy of patients with diffuse large B-cell lymphoma. Leukemia & Lymphoma 2015, 56: 2579-2584. PMID: 25629993, DOI: 10.3109/10428194.2015.1007506.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDisease-Free SurvivalDoxorubicinFemaleFluorodeoxyglucose F18HumansLymphoma, Large B-Cell, DiffuseMaleMiddle AgedOutcome Assessment, Health CarePositron-Emission TomographyPrednisoneProportional Hazards ModelsRemission InductionRetrospective StudiesRituximabTomography, X-Ray ComputedVincristineYoung AdultConceptsDiffuse large B-cell lymphomaFluorodeoxyglucose positron emission tomography-computed tomographyPositron emission tomography-computed tomographyEmission tomography-computed tomographyLarge B-cell lymphomaFirst-line therapyMajority of patientsTomography-computed tomographyB-cell lymphomaI-PETPET/CTFrontline therapyClinical utilityInterim PET/CTTreatment PET/CTProgression-free survivalEnd of treatmentLittle clinical utilityPost-treatment assessmentRetrospective studyPretreatment stagingMultivariable modelingPatientsTreatment imagingTherapyWhat is the role of dosimetry in patients with advanced thyroid cancer?
Chen MK, Cheng DW. What is the role of dosimetry in patients with advanced thyroid cancer? Current Opinion In Oncology 2015, 27: 33-37. PMID: 25319079, DOI: 10.1097/cco.0000000000000145.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPositron emission tomography-computed tomographyThyroid cancerLesional dosimetryPretreatment dosimetryAdvanced differentiated thyroid cancerEmission tomography-computed tomographyIntermediate-risk patientsAdvanced thyroid cancerMetastatic thyroid cancerDifferentiated thyroid cancerTomography-computed tomographyRenal insufficiencyElderly patientsRenal failureRisk patientsProlonged withdrawalPatientsHigh dosesThyroid hormonesSimilar outcomesTreatment dosageCancerRole of dosimetryUptake of iodineWhole body
2014
Use of (18)F-fluorodeoxyglucose positron emission tomography-computed tomography to aid in diagnosing intestinal adenocarcinoma in 2 rhesus macaques (Macaca mulatta).
Caporizzo DJ, Kwiatkowski AE, Chen MK, Beck AP, Booth CJ, Zeiss C, Smith PC, Carlson Scholz JA, Wilson SR. Use of (18)F-fluorodeoxyglucose positron emission tomography-computed tomography to aid in diagnosing intestinal adenocarcinoma in 2 rhesus macaques (Macaca mulatta). Journal Of The American Association For Laboratory Animal Science 2014, 64: 211-20. PMID: 24956213, PMCID: PMC4067585.Peer-Reviewed Case Reports and Technical NotesConceptsIntestinal adenocarcinomaAdvanced ageFluorodeoxyglucose positron emission tomography-computed tomographyPositron emission tomography-computed tomographyPositron emission tomography-CTEmission tomography-computed tomographyRhesus macaquesAged female rhesus macaquesInconclusive radiographic findingsFocal FDG uptakeTomography-computed tomographyNoninvasive diagnostic toolFemale rhesus macaquesExploratory laparotomyFDG uptakeFDG-PETGastrointestinal adenocarcinomasRadiographic findingsTomography-CTClinical signsTransmural massAdenocarcinomaSmall intestineConventional radiographyNonhuman primates
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply